Abingdon Health Plc (AIM: ABDX)

Market Cap	37.15M
Revenue (ttm)	5.34M
Net Income (ttm)	-2.24M
Shares Out	381.06M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,096
Open	n/a
Previous Close	9.75
Day's Range	9.50 - 10.00
52-Week Range	6.50 - 14.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 17, 2024

About Abingdon Health

Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally. The company provides Abingdon Simply Test, a range of self-tests in the field of fertility, health and well-being, infectious diseases, and drug testing; PCRD and PCRD FLEX, are nucleic acid lateral flow tests, which are used for rapid readouts post isothermal amplification; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 82
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: ABDX

Financial Performance

In 2023, Abingdon Health's revenue was 4.05 million, an increase of 42.68% compared to the previous year's 2.84 million. Losses were -3.45 million, -83.77% less than in 2022.